UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2025 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 230 Park Avenue Suite 3350 New York, New Yo ...

Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerability and validity of SADA PRIT platform pre-targeting approach; Company expects to present Part A data in the second quarter of 2025 Company reports preliminary estimated unaudited Total Net Revenue of approximately $88 million for the year ended December 31, 2024 ...

Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerability and validity of SADA PRIT platform pre-targeting approach; Company expects to present Part A data in the second quarter of 2025 Company reports preliminary estimated unaudited Total Net Revenue of approximately $88 million for the year ended December 31, 2024 ...

Company Leadership Changes - Sue Smith, Chief Commercial Officer, will be departing the organization [1] - Doug Gentilcore appointed as Senior Vice President, Head of DANYELZA Business Unit [4] - Doug Gentilcore brings over two decades of strategic leadership experience in the pharmaceutical industry [5] Product Information - DANYELZA® (naxitamab-gqgk) is indicated for the treatment of pediatric and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow [1] - DANYELZA® includes a Boxed Warning for serious infusion-related reactions and neurotoxicity [1] - DANYELZA is currently not approved for the treatment of osteosarcoma in any jurisdiction [2] Company Overview - Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic cancer products [3] - The Company's technologies include its investigational SADA PRIT Platform and bispecific antibodies generated using the Y-BiClone platform [3] - The Company's product pipeline includes the anti-GD2 therapy DANYELZA® [3] Future Plans and Expectations - Doug Gentilcore's experience is expected to be instrumental in the continued commercial expansion and growth of DANYELZA beyond pediatric oncology [5]

Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerability and validity of SADA PRIT platform pre-targeting approach; Company expects to present Part A data in the second quarter of 2025 Company reports preliminary estimated unaudited Total Net Revenue of approximately $88 million for the year ended December 31, 2024, wi ...

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025 at 5:15 p.m. P ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2024 Earnings Conference Call November 8, 2024 8:00 AM ET Company Participants Courtney Dugan - Head-IR Michael Rossi - President & CEO Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Peter Pfreundschuh - CFO Conference Call Participants Etzer Darout - BMO Capital Markets Li Watsek - Cantor Fitzgerald Alec Stranahan - Bank of America Justin Walsh - JonesTrading Jeff Jones - Oppenheimer David Nierengarten - Wedbush Securities Nicole Germin ...

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -14.29%. A quarter ago, it was expected that this company would post a loss of $0.13 per share when it actually produced a loss of $0.21, delivering a surprise of -61.54%.Over the last four quarters, the company ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-mAbs Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4619612 (State or ...

Exhibit 99.1 Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments ● Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024 ● Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment of $2.0 million in the fourth quarter of 2024 ● Achieved extension of primary DANYELZA U.S. patent through February 2034 ● Continued geographic expansion of DANYELZA with new market revenue ...